IL-1Ra

DRUG5 trials

Sponsors

University of Zurich, Reza Dana, MD, Marc Y.Donath, University of Manchester, Beijing Tongren Hospital

Conditions

BlepharokeratoconjunctivitisCorneal NeovascularizationSubarachnoid HemorrhageType 2 Diabetes

Phase 1

Topical IL-1-Ra for Treatment of Corneal Neovascularization

TerminatedNCT00915590

Reza Dana, MDCorneal Neovascularization

Start: 2009-04-30End: 2011-03-31Updated: 2017-05-08

Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects

Beijing Tongren HospitalBlepharokeratoconjunctivitis

Start: 2017-12-18End: 2018-06-10Target: 34Updated: 2017-12-26

Phase 2

Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist

CompletedNCT00303394

University of ZurichType 2 Diabetes

Start: 2004-04-30End: 2006-03-31Target: 72Updated: 2007-03-05

Phase 3

SC IL-1Ra in SAH - Phase III Trial (SCIL)

University of ManchesterSubarachnoid Hemorrhage

Start: 2018-10-11End: 2024-09-30Updated: 2023-11-21

Unknown Phase

Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During Exercise

CompletedNCT01771445

Marc Y.DonathType 2 Diabetes

Start: 2011-12-31End: 2013-10-31Updated: 2014-01-08

Related Papers

Muscle-Derived IL-6 Is Not Regulated by IL-1 during Exercise. A Double Blind, Placebo-Controlled, Randomized Crossover Study

PLoS ONE2015-10-089 citations

Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

2007-04-011332 citations